Liraglutide (Saxenda/Victoza)
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Liraglutide is a once-daily injectable GLP-1 (glucagon-like peptide-1) receptor agonist. It is a synthetic analogue of a naturally occurring gut hormone released after eating, modified to resist rapid breakdown so that a single daily dose can sustain its activity. It is one of the earlier GLP-1 medications to reach the market and remains widely studied.
The same molecule is marketed under two brand names for two different purposes. As Saxenda, it is FDA-approved for chronic weight management alongside a reduced-calorie diet and increased physical activity. As Victoza, it is approved to improve blood-sugar control in adults with type 2 diabetes, and it has also been studied for its effect on cardiovascular risk in that population.
Liraglutide belongs to the same drug class as semaglutide and tirzepatide, but differs in that it is administered daily rather than weekly. Its efficacy for weight loss and glucose control has been evaluated in large randomized trials.
How it works
Liraglutide activates the GLP-1 receptor, mimicking the action of the body’s own incretin hormone. This enhances insulin secretion in a glucose-dependent manner — meaning insulin is released mainly when blood sugar is elevated — and suppresses glucagon, which together help regulate blood-sugar levels.
Beyond its effect on glucose, liraglutide slows the rate at which the stomach empties and acts on appetite-regulating centers in the brain, which is commonly reported to increase satiety and reduce food intake. These combined effects are thought to underlie its studied roles in both diabetes management and weight reduction.
Reported benefits
- Studied for meaningful weight loss when combined with diet and exercise (SCALE trials)
- Improved blood-sugar control in type 2 diabetes
- Reduced appetite and increased feelings of fullness commonly reported
- Reduction in major cardiovascular events observed in high-risk type 2 diabetes patients (LEADER trial)
These are reported and studied effects, not guaranteed outcomes, and results vary between individuals.
Considerations & side effects
The most commonly reported side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which are often most noticeable when treatment begins or the dose is increased. Because liraglutide slows gastric emptying, these effects tend to be dose-related and may ease over time.
Labeling for liraglutide carries a boxed warning regarding the risk of thyroid C-cell tumors observed in rodents; its relevance to humans is not established, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Other considerations reported in trials include pancreatitis, gallbladder events, and low blood sugar (particularly when combined with other glucose-lowering medications). It is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is liraglutide?
Liraglutide is a once-daily injectable GLP-1 receptor agonist — a synthetic analogue of the gut hormone GLP-1 — that enhances glucose-dependent insulin release, slows gastric emptying, and reduces appetite. It is sold under the brand names Saxenda and Victoza.
Is liraglutide FDA-approved?
Yes. It is FDA-approved as Saxenda for chronic weight management and as Victoza for the treatment of type 2 diabetes. The two brands share the same active ingredient but are approved at different doses for different uses.
What is the difference between Saxenda and Victoza?
Both contain liraglutide. Saxenda is approved for weight management, while Victoza is approved to improve blood-sugar control in type 2 diabetes and to reduce cardiovascular risk in certain patients. They differ in their approved dosing and labeled indications.
How does liraglutide compare with semaglutide?
Both are GLP-1 receptor agonists, but liraglutide is dosed once daily while semaglutide is typically dosed once weekly. Head-to-head studies have generally reported greater average weight loss with semaglutide, though individual responses vary.
How is liraglutide administered?
It is given by subcutaneous injection using a prefilled pen, most commonly into the abdomen, thigh, or upper arm.
References
- Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). N Engl J Med. ↗
- Davies MJ, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. ↗
- Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. ↗
Related compounds
Long-acting amylin receptor agonist for weight management. Combined with semaglutide in CagriSema, showing up to 22.7% weight loss in Phase III trials.
Weight blend combining the amylin analog cagrilintide with the GIP/GLP-1 dual agonist tirzepatide, targeting satiety and glycemic pathways together. No human trial of this exact combination; research-level, sold pre-blended.
Dual-mechanism weight blend pairing the long-acting amylin analog cagrilintide with the GLP-1 agonist semaglutide (1:1). Novo Nordisk's clinical program showed greater weight loss than either component alone. Sold as a single co-lyophilized vial.